PROCEPT BioRobotics Corporation Increase (Decrease) in Accounts Receivable
PROCEPT BioRobotics Corporation (PRCT) reported Increase (Decrease) in Accounts Receivable of $24.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $11.63M, a 329.82% increase year-over-year.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $13.32M.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$2.23M, a 115.04% decline year-over-year.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $4.35M, a 58.90% decline year-over-year.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for fiscal 2025 was $898.00K, a 97.50% decline from fiscal 2024.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for fiscal 2024 was $35.96M, a 8.63% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for fiscal 2023 was $33.10M, a 206.25% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation increase (decrease) in accounts receivable for fiscal 2022 was $10.81M, a 270.93% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.95M 10-Q · filed 2026-08-05 | $22.72M derived: sum of 3 quarters · filed 2026-08-05 | $27.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $13.32M 10-Q · filed 2026-04-30 | $11.09M derived: sum of 2 quarters · filed 2026-04-30 | $15.44M derived: sum of 3 quarters · filed 2026-04-30 | $18.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.12M derived: sum of 2 quarters · filed 2026-02-26 | $4.83M derived: sum of 3 quarters · filed 2026-08-05 | $898.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.06M derived: sum of 2 quarters · filed 2026-08-05 | $3.13M 10-Q · filed 2025-11-05 | $17.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.22M 10-Q · filed 2026-08-05 | $13.61M derived: sum of 3 quarters · filed 2026-08-05 | $24.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.93M 10-Q · filed 2026-04-30 | $10.90M derived: sum of 2 quarters · filed 2026-04-30 | $21.49M derived: sum of 3 quarters · filed 2026-04-30 | $24.32M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.42M derived: sum of 2 quarters · filed 2026-02-26 | $28.25M derived: sum of 3 quarters · filed 2026-02-26 | $35.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.42M derived: sum of 2 quarters · filed 2025-11-05 | $21.13M 10-Q · filed 2025-11-05 | $34.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $10.54M 10-Q · filed 2025-08-07 | $24.30M derived: sum of 3 quarters · filed 2026-02-26 | $25.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $7.71M 10-Q · filed 2025-05-02 | $21.46M derived: sum of 2 quarters · filed 2026-02-26 | $22.91M derived: sum of 3 quarters · filed 2026-02-26 | $35.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $13.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.20M derived: sum of 2 quarters · filed 2026-02-26 | $27.73M derived: sum of 3 quarters · filed 2026-02-26 | $33.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-28 | $13.98M derived: sum of 2 quarters · filed 2024-10-28 | $19.35M 10-Q · filed 2024-10-28 | $21.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $12.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $17.90M 10-Q · filed 2024-08-02 | $20.34M derived: sum of 3 quarters · filed 2025-02-27 | $22.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.37M 10-Q · filed 2024-05-02 | $7.80M derived: sum of 2 quarters · filed 2025-02-27 | $9.75M derived: sum of 3 quarters · filed 2025-02-27 | $13.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.38M derived: sum of 2 quarters · filed 2025-02-27 | $8.28M derived: sum of 3 quarters · filed 2025-02-27 | $10.81M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.85M derived: sum of 2 quarters · filed 2023-11-02 | $8.38M 10-Q · filed 2023-11-02 | $6.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $6.43M 10-Q · filed 2023-07-28 | $4.54M derived: sum of 3 quarters · filed 2024-02-28 | $5.75M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.53M 10-Q · filed 2023-05-04 | $639.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.85M derived: sum of 3 quarters · filed 2024-02-28 | $2.86M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$677.00K derived: sum of 2 quarters · filed 2024-02-28 | $330.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.91M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $2.22M derived: sum of 2 quarters · filed 2022-11-04 | $4.80M 10-Q · filed 2022-11-04 | $4.59M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $3.59M 10-Q · filed 2022-08-05 | $3.37M derived: sum of 3 quarters · filed 2022-08-05 | |
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-06 | $2.37M derived: sum of 2 quarters · filed 2022-05-06 | ||
| 2020-12-31 | -$218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $511.00K 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $729.00K 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |